Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis

Area of Science:

• Cardiology
• Medical Devices
• Hemodynamics

Background:

• The Impella CP is a vital tool for managing cardiogenic shock but is associated with significant hemolysis.
• Optimizing device placement, volume status, and anticoagulation can mitigate hemolysis risk, yet it sometimes persists.

Observation:

• This case series examined eight patients with cardiogenic shock experiencing refractory hemolysis after Impella CP implantation.
• Half of these patients required continuous renal replacement therapy, with rising plasma free hemoglobin (pFHb) and lactate dehydrogenase levels.
• Refractory hemolysis was diagnosed a median of 16.5 hours post-Impella CP placement.

Findings:

• Upgrading to the Impella 5.0 or 5.5 version was performed a median of 6 hours after hemolysis diagnosis.
• 87.5% of patients showed a significant drop in pFHb levels within 72 hours post-upgrade.
• Most patients were discharged without requiring further dialysis; one patient succumbed to multi-organ failure.

Implications:

• Early identification and management of Impella-associated hemolysis through close pFHb monitoring are crucial.
• Upgrading to the Impella 5.5 device can reduce hemolysis, preserve renal function, and enhance patient survival in cardiogenic shock.
• This strategy offers a potential solution for refractory hemolysis in patients supported by temporary mechanical circulatory support.